Do eating disorders accompany metabolic syndrome in psoriasis patients? Results of a preliminary study

Ilknur Altunay 1
Gulsen Tukenmez Demirci 1
Bilge Ates 1
Aslı Kucukunal 1
Cigdem Aydin 2
Oguz Karamustafaloglu 3
Yuksel Altuntas 4

1Dermatology Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 2Psychology Department, Istanbul University, Istanbul, Turkey; 3Psychiatry Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey; 4Internal Medicine Endocrinology Department, Sisli Etfal Training and Research Hospital, Istanbul, Turkey

Background: Metabolic syndrome (MBS) has been reported as a frequent comorbidity in psoriatic patients. The main pathogenesis is considered to be inflammation in this association. MBS has been investigated in eating disorders as well. While psoriasis has some psychiatric comorbidities, the link between psoriasis, MBS, and eating disorders (EDs) is unknown.

Methods: The study was designed as a cross-sectional, randomized, and controlled trial. A total of 100 patients with psoriasis were included in the study. Sociodemographic data, clinical subtype of psoriasis, Psoriasis Area and Severity Index (PASI) scores, and associated diseases were registered for each patient. The criteria for diagnosis of MBS developed by the International Diabetes Foundation (IDF) was used. These are central obesity (waist circumference $\geq 94$ cm in men or $\geq 80$ cm in women), plus two of the following: elevated triglycerides ($\geq 150$ mg/dL), reduced high-density lipoprotein cholesterol ($\leq 40$ mg/dL for men; $\leq 50$ mg/dL for women), elevated blood pressure ($\geq 130$ mmHg systolic or $\geq 85$ mmHg diastolic), and elevated fasting blood glucose ($\geq 100$ mg/dL). Additionally, the Eating Attitude Test (EAT), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI), and psychiatric interview were performed for all patients.

Results: There were 45 female and 55 male patients, aged between 18 and 85 years old (median 41.12 ± 16.01). MBS was present in 31% of the patients with psoriasis. There was no correlation between the severity of psoriasis and MBS. EAT scores were 30 in 7/100 patients. Four out of 31 patients with MBS (12.9%) had ED and 3/69 patients were without MBS (4.3%). Mean ED scores were compared statistically and the difference was significant (EAT $= 17.9 \pm 9.558$ and $11.5 \pm 7.204$, $P < 0.001$).

Conclusion: Defining risk factors leading to comorbidities is important in psoriasis. EDs seem to have an impact on the development of MBS in psoriasis. Establishment and treatment of EDs in patients with psoriasis may prevent the onset of MBS and other comorbidities due to MBS.

Keywords: obesity, abdominal obesity, binge-eating disorder, anxiety, inflammation

Introduction
Psoriasis is a chronic inflammatory skin disease. Variable immunological and inflammatory processes play a role in pathogenesis and also contribute to occurrence of comorbidities. While the more common concomitant disorders are psoriatic arthritis and depression/anxiety, research papers of comorbidities due to metabolic disregulation and resultant metabolic syndrome (MBS) gradually increase.1–8 MBS is particularly important, because it includes a cluster of risk factors such as central obesity, hypertension, abnormal glucose intolerance, and dyslipidemia, all of which are strong
predictors of cardiovascular disease, diabetes mellitus, and stroke.\textsuperscript{9,11} All these comorbidities are complex and are supposed to share common pathogenetic pathways and cytokine profiles with psoriasis. Moreover, it is also important to be aware of some predisposing factors, such as sedentary life style, smoking, and alcoholism, which have been previously considered to be facilitating factors for the development of MBS in patients with psoriasis.\textsuperscript{12}

Eating disorders (EDs) are characterized by clinically significant disturbances in eating behavior. They are often accompanied by another psychiatric disorder such as depression and anxiety. Particularly, binge-eating disorder (BED) may be associated with obesity and MBS.\textsuperscript{12,13} Hence, it is logical to consider that EDs are psychogenic cofactors which may contribute to the development of MBS in psoriatic patients who are also prone to various psychiatric comorbidities; for example, depression and anxiety.\textsuperscript{14–16}

While a few studies demonstrate a link between MBS and EDs,\textsuperscript{17–19} there are also some studies implicating a relationship between EDs and anxiety.\textsuperscript{20–22} If there is a relationship between EDs and psoriasis, diagnosing any ED would be useful for suggesting a change in eating behavior of a psoriatic patient with MBS and thus improve resultant MBS.

\section*{Materials and methods}

The study was designed as a cross-sectional, randomized, and controlled trial. A total of 100 patients with psoriasis (55 males, 45 females, age range 18–85, mean age 41.12 ± 16.01) were included in the study. Sociodemographical data including sex, age, marital status and educational status, clinical subtype of psoriasis, psoriasis area severity index (PASI) scores, and other systemic diseases were registered for each patient. Additionally, Eating attitudes Test (EAT), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) were performed on all patients.

EAT-26 is a widely used self-report measure of EDs, and although it was developed by Garner and Garfinkel in 1979\textsuperscript{23} to measure symptoms of anorexia nervosa (AN), it has been used in nonclinical samples as a general screening measure for disordered eating attitudes. EAT-26 is based on EAT-40 and was adapted to Turkish by Erol and Savasir in 1989.\textsuperscript{24} Total scores on EAT-26 are derived as a sum of the composite items, ranging from 0 to 53, with a score of 20 used as the cutoff.\textsuperscript{24} The Turkish version of EAT consists of 40 questions, the answers to which are evaluated with a six-point Likert scale, from “always” to “never.” The resulting scores range between 0 and 120 points, and individuals scoring ≥30 points are considered as at high risk of EDs.\textsuperscript{24}

The Turkish versions of BDI and BAI, reliability and validity studies of which had been previously performed in the Turkish population, were used.\textsuperscript{25–28}

All patients were evaluated for the presence of MBS. The criteria developed by the International Diabetes Foundation for diagnosis of MBS was used. These criteria are central obesity (waist circumference ≥94 cm in men or ≥80 cm in women), plus two of the following: triglycerides ≥150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL for men or <50 mg/dL for women; blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic; and fasting blood glucose ≥100 mg/dL. Two study groups were formed according to these criteria. Group 1 consisted of the patients who met MBS criteria, and Group 2 consisted of the patients who did not meet MBS criteria. These two groups were compared statistically in terms of sociodemographical factors and the presence of MBS, EDs, depression, and anxiety. The patients who had an ED according to EAT were also evaluated by a psychiatrist, and the ED was confirmed by psychiatric examination and Diagnostics and Statistical Manual of Mental Disorders, 4th edition criteria.\textsuperscript{29}

Patients who were found to have an ED were assessed according to EAT, and a psychiatric interview was done by a psychiatrist. The patients were classified as having AN, bulimia nervosa (BN), BED, or an ED not otherwise specified (ED-NOS). Independent samples t-test, Mann–Whitney U-test, chi-square test, Fisher’s exact test, and SPSS Statistics 11.5 (IBM Corporation, Somers, NY) software for Windows\textsuperscript{®} were used for statistical assessments. \( P < 0.05 \) was considered statistically significant.

\section*{Results}

Group 1 consisted of 31 patients with MBS (31\%, mean age 48.5 ± 13.4), and Group 2 consisted of 69 patients (69\%, mean age 37.7 ± 16.0). When the two groups were compared, all parameters including sex, marital status, educational status, disease duration, type of psoriasis according to onset age (type 1 and type 2), and disease severity determined by PASI values except for age were statistically insignificant (Table 1). EAT scores were ≥30 in 7 out of 100 patients. Four out of 31 patients with MBS (12.9\%) and 3 out of 69 patients without MBS (4.3\%) had an ED. However, statistical evaluation was impossible because of low numbers of patients; therefore, mean ED scores were evaluated and a statistically significant difference was found (EAT = 17.9 ± 9.558 and 11.5 ± 7.204, \( P < 0.001 \)) (Figure 1). In psychiatric evaluation, three out of four patients (75\%) had BED and one (25\%) had ED-NOS in
Group 1. Two out of three patients (67%) had BED, and one (33%) had ED-NOS. No patients had AN or BN.

When the relationship between EDs and depression/anxiety scores was considered, mean BAI scores of the patients with an ED were higher than those without an ED, and the statistical difference was significant ($P = 0.004$) (Table 2). In addition, when the presence of anxiety is considered, the difference between the patients with an ED and those without an ED was statistically significant ($P = 0.002$). BDI did not show any correlation with ED scores; thus, the existence of depression was not related to an ED.

The relationship between PASI and other parameters (criteria of MBS, anxiety, and depression) was evaluated statistically. Only the presence of depression revealed a significant difference ($P = 0.031$).

**Discussion**

Psoriasis is a chronic, immunologically based, inflammatory disease associated with many comorbidities related to immune-mediated inflammation and metabolic dysregulation. In particular, recent studies have focused on the MBS and its components such as atherogenesis, hypertension, and insulin resistance. It is hypothesized that proinflammatory cytokines and pathomechanisms in inflammation are shared in both psoriasis and MBS. In fact, this association alone was proven; it was not considered a causality. Hence, a new problem has emerged with additional risk factors such as cigarette smoking, excessive alcohol consumption, and obesity, which predispose psoriatic patients to develop MBS.

**Table 1** Demographic and clinical characteristics of psoriatic patients with MBS and without MBS

<table>
<thead>
<tr>
<th>Patients with MBS (n = 31)</th>
<th>Patients without MBS (n = 69)</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male/female</td>
<td>17/14</td>
<td>38/31</td>
</tr>
<tr>
<td>Age, mean ± SD</td>
<td>48.55 ± 13.46</td>
<td>37.78 ± 16.03</td>
</tr>
<tr>
<td>Disease duration, mean ± SD</td>
<td>13.72 ± 10.65</td>
<td>10.18 ± 9.54</td>
</tr>
<tr>
<td>PASI, mean ± SD</td>
<td>13.92 ± 11.01</td>
<td>16.52 ± 12.32</td>
</tr>
<tr>
<td>PASI &gt; 10, n (%)</td>
<td>17 (54.8)</td>
<td>36 (52.2)</td>
</tr>
<tr>
<td>Type of psoriasis, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type 1</td>
<td>20 (64.5)</td>
<td>54 (78.3)</td>
</tr>
<tr>
<td>Type 2</td>
<td>11 (35.5)</td>
<td>15 (21.7)</td>
</tr>
</tbody>
</table>

**Abbreviations**: MBS, metabolic syndrome; PASI, psoriasis area severity index; sD, standard deviation.

**Table 2** Beck anxiety and Beck depression mean scores in psoriatic patients with EDs and without EDs (Mann–Whitney U-test; 95% confidence interval)

<table>
<thead>
<tr>
<th>Eating attitudes test-40</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ± SD</td>
<td>Mean ± SD</td>
</tr>
<tr>
<td>Age</td>
<td>37.71 ± 9.55</td>
</tr>
<tr>
<td>PASI</td>
<td>14.70 ± 8.08</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>7.50 ± 4.75</td>
</tr>
<tr>
<td>Beck anxiety score (mean)</td>
<td>21.86 ± 6.09</td>
</tr>
<tr>
<td>Beck depression</td>
<td>18.14 ± 13.36</td>
</tr>
</tbody>
</table>

**Abbreviations**: ED, eating disorder; PASI, psoriasis area severity index; sD, standard deviation.

*Figure 1* Mean scores of EAT in patients with MBS and patients without MBS (EAT = 17.900 ± 9.558 and 11.500 ± 7.204, $P < 0.001$). **Abbreviations**: EAT, eating attitudes test; MBS, metabolic syndrome.
number of patients was inadequate for statistical comparison for EDs. This may be a limitation of this present study. More reliable or indicative results are likely with a larger number of psoriatic patients. When considering the prevalence of EDs, there are different studies in different populations. Women, children, adolescents, and the obese have been the principal subjects for prevalence studies. In a large-scale prevalence study including six European countries, AN 0.48%, BN 0.51%, and BED 1.12% were found. Therefore, working with larger numbers of patients would probably be more indicative because of the small percentage of real EDs in the general population.

These data raise another question as to why psoriatic patients have EDs. The explanation comes from increased psychiatric comorbidity, in particular depression and anxiety, in psoriatic patients. There are some reports that indicate a link between ED and stress factors including anxiety and depression. This means that, in particular, anxiety associated with psoriasis may cause abnormal eating habits and resultant MBS in psoriasis. In a study conducted by Herron et al obesity was suggested as a consequence of psoriasis and not a risk factor for onset of disease. Accordingly, the authors of this present paper suggest that the interaction between psoriasis, psychiatric symptoms, and EDs may lead to obesity or MBS over time; that these current results showed higher mean age in MBS may reinforce this speculation.

According to this study’s findings, clinical severity of psoriasis measured by PASI seems to be an independent variable in the relationship between EDs, MBS, and anxiety.

Conclusion
In conclusion, it appears that it is not adequate to establish the presence of comorbidities alone; defining risk factors leading to comorbidities is also important in patients with psoriasis. If causative factors are detected, controlling them by a multidisciplinary approach will prevent the onset of comorbidities and also provide both cost-effective and satisfactory management of psoriasis.

Disclosure
The authors report no conflicts of interest in this work.

References


